Undisclosed aaRS-targeting program(s)
Oncology
Pre-clinicalActive
Key Facts
About Oxford Drug Design
Oxford Drug Design is a private, pre-clinical stage biotech with a distinctive dual-platform strategy combining deep biological expertise in tRNA synthetases (aaRS) with a proprietary AI/ML computational discovery engine. This integrated approach is applied to identify novel disease targets and advance drug candidates, with a current pipeline focused on oncology. The company operates from its Oxford, UK headquarters and appears to be pre-revenue, relying on investment and partnerships to fund its research and development activities. Its core proposition is the acceleration of drug discovery through a targeted, AI-powered platform against a validated but underexplored enzyme family.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |